Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer

Marta Sandini; Manuel Patiño; Cristina R. Ferrone; Carlos A. Alvarez-Pérez; Kim C. Honselmann; Salvatore Paiella; Matteo Catania; Luca Riva; Giorgia Tedesco; Raffaella Casolino; A. Auriemma; Maria Chiara Salandini; Giulia Carrara; Giulia Cristel; Anna Damascelli; Davide Ippolito; Mirko D’Onofrio; Keith D. Lillemoe; Claudio Bassi; Marco Braga; Luca Gianotti; Dushyant V. Sahani; Carlos Fernández-del Castillo

doi:10.1001/jamasurg.2018.0979

Abstract

This is the authors' abstract. We don't add key points for this paper.

Patients with PC experience a significant loss of adipose tissue during neoadjuvant chemotherapy, but no muscle wasting. An increase in muscle tissue during NT is associated with resectability.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sandini et al. (2018) studied this question.

synapsesocial.com/papers/69d8b3e88cb8f39931ae39d8 https://doi.org/10.1001/jamasurg.2018.0979

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

Patients with PC experience a significant loss of adipose tissue during neoadjuvant chemotherapy, but no muscle wasting. An increase in muscle tissue during NT is associated with resectability.

Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer

Abstract

Ask about this paper

Discussion

Cite This Study

Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading